U.S. markets open in 1 hour 38 minutes
  • S&P Futures

    4,541.25
    +4.75 (+0.10%)
     
  • Dow Futures

    35,560.00
    +3.00 (+0.01%)
     
  • Nasdaq Futures

    15,381.00
    +40.00 (+0.26%)
     
  • Russell 2000 Futures

    2,286.70
    -2.10 (-0.09%)
     
  • Crude Oil

    84.68
    +0.92 (+1.10%)
     
  • Gold

    1,801.80
    +5.50 (+0.31%)
     
  • Silver

    24.45
    +0.01 (+0.02%)
     
  • EUR/USD

    1.1610
    -0.0035 (-0.30%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • Vix

    15.91
    +0.90 (+6.00%)
     
  • GBP/USD

    1.3753
    -0.0006 (-0.05%)
     
  • USD/JPY

    113.6500
    +0.1900 (+0.17%)
     
  • BTC-USD

    62,786.33
    +2,371.42 (+3.93%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,230.23
    +25.68 (+0.36%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.


Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2020 results on Tuesday, August 11, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and corporate developments.

The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 8855368 approximately 15 minutes prior to the call.

To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Investor & Media Contact:

Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel: (917) 436-8102